|
 | Up a level |
Banerjee, Sube, Farina, Nicolas, Henderson, Catherine, High, Juliet, Stirling, Susan, Shepstone, Lee, Fountain, Julia, Ballard, Clive, Bentham, Peter, Burns, Alistair, Fox, Chris, Francis, Paul, Howard, Robert, Knapp, Martin, Leroi, Iracema, Livingston, Gill, Nilforooshan, Ramin, Nurock, Shirley, O’Brien, John, Price, Annabel, Thomas, Alan J., Swart, Ann Marie, Telling, Tanya and Tabet, Naji (2023) A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial. Health Technology Assessment, 27 (23). 1 - 108. ISSN 1366-5278
Henderson, Catherine, Knapp, Martin, Stirling, Susan, Shepstone, Lee, High, Juliet, Ballard, Clive, Bentham, Peter, Burns, Alistair, Farina, Nicolas, Fox, Chris, Fountain, Julia, Francis, Paul, Howard, Robert, Leroi, Iracema, Livingston, Gill, Nilforooshan, Ramin, Nurock, Shirley, O’brien, John T., Price, Annabel, Swart, Ann Marie, Tabet, Naji, Telling, Tanya, Thomas, Alan J. and Banerjee, Sube (2022) Cost-effectiveness of mirtazapine for agitated behaviors in dementia: findings from a randomized controlled trial. International Psychogeriatrics, 34 (10). 905 - 917. ISSN 1041-6102
